<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        ŌURA has partnered with Clue, a period and reproductive health tracking app, to bring a new integrated solution that bridges Clue's menstrual health tracking with ŌURA's biometric sensing abilities, allowing users to monitor body temperature trends. They're especially focusing on research relating to perimenopause.
      </p>
    </li>
    <li>
      <p>
        In addition, plans to expand the integration to include other biometric data, like sleep tracking, are underway. This partnership aims to provide insights into personal health management and assist in uncovering neglected areas in women's health.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://femtechinsider.com/clue-oura-partnership/">
      Fem Tech Insider
    </a>
  </p>
  <p>
  </p>
</div>


Fertility Tech

PROMINENT_CATEGORY

<div>
    <ul>
        <li>
            <p>ŌURA has partnered with Clue, a period and reproductive health tracking app, to bring a new integrated solution. This solution combines Clue's menstrual health tracking with ŌURA's biometric sensing abilities. Users can monitor body temperature trends, with a focus on research relating to perimenopause.</p>
        </li>
        <li>
            <p>Furthermore, there are plans to expand the integration to include other biometric data, such as sleep tracking. The partnership aims to provide insights into personal health management and uncover neglected areas in women's health.</p>
        </li>
    </ul>
</div>

ŌURA and Clue partner to enhance personal health management and reproductive health research

<div>
 
 <ul>
  <li><p>Initox has raised USD 6 million in Series A funding led by Fireside Ventures. The funds are expected to be used to build advanced analytics capabilities with the help of AI.</p></li>
  <li><p>California-based Inito's home fertility monitoring kit is designed to track estrogen, LH, progesterone metabolite PdG and FSH on a single test strip, reportedly providing a fuller picture of a woman's fertility window. It is claimed that Inito provides numerical values of fertility hormones and personalizes results as well as confirm if the user actually ovulates by looking at the rise in progesterone metabolite PdG.</p></li>
 </ul>
 
</div>

Inito raises USD 6 million in Series A funding to advance its capabilities

<div>
 
 <ul>
  <li><p>Ovia Health has introduced a new fertility and family-building benefit for employers and health plans, providing financial and informational support for individuals starting families.</p></li>
  <li><p>The package includes the Ovia Wallet, funded by employers, which covers eligible expenses like IVF, adoption, and surrogacy. It offers multiple payment options, including a digital wallet, debit card, and reimbursement schemes. The offering also includes care navigation services and personalized support in finding fertility clinics and adoption agencies.</p></li>
  <li><p>Ovia Health, a subsidiary of Labcorp, is a family health benefits platform that offers personalized and data-driven solutions for fertility, pregnancy, and parenting. The company has over 10 million users for its health app for women and families.</p></li>
 </ul>
 
</div>

Ovia Health launches fertility and family-building benefit

<div>
 
 <ul>
  <li><p>Boston IVF has acquired the fertility care center of Rochester Regional Health in Rochester, New York, to improve access to patients in the Greater Rochester Region and Western New York.</p></li>
  <li><p>The fertility team in Rochester will remain the same under Boston IVF.</p></li>
  <li><p>Boston IVF, based in Massachusetts, provides a range of fertility services including consultations, appointments, treatment management, IUI procedures, monitoring, IVF procedures, and egg freezing at its fertility center in Syracuse, NY.</p></li>
 </ul>
 
</div>

Boston IVF acquires Rochester Regional Health's fertility care center in New York

<div>
 <ul>
  <li><p>Diagnostics and lifestyle product provider ŌURA has partnered with Cronometer, a nutrition tracking app to launch a collaborative new feature for menstrual cycle tracking.</p></li>
  <li><p>The new feature integrates ŌURA’s Cycle Insights into the Cronometer app to provide a detailed understanding of menstrual health. This allows users of the Oura Ring and Cronometer app to track certain aspects of their menstrual cycle, such as the luteal and follicular phases, body temperature changes, and associated symptoms. The aim is to correlate menstrual health data with other health metrics to provide a broader perspective on overall health.</p></li>
  <li><p>The feature’s full benefits are currently accessible only to customers of both Oura Ring and the Cronometer app. However, future updates are expected to allow all Cronometer users to manually add their menstrual cycle data, expanding the feature’s accessibility.</p></li>
 </ul>
</div> 

Diagnostics and lifestyle provider ŌURA has partnered with Cronometer to launch a new feature for menstrual cycle tracking. This feature integrates ŌURA's Cycle Insights into the Cronometer app, allowing users of the Oura Ring and Cronometer app to track various aspects of their menstrual cycle. This includes the luteal and follicular phases, body temperature changes, and associated symptoms. The goal is to correlate menstrual health data with other health metrics for a broader view of overall health. At present, the full benefits of the feature are available only to customers of both Oura Ring and Cronometer app. However, future updates will expand accessibility to all Cronometer users who can manually add their menstrual cycle data.

ŌURA partners with Cronometer to launch collaborative new feature for menstrual cycle tracking

<div>
 <ul>
  <li><p>INVO Bioscience and NAYA Biosciences have entered a merger agreement worth USD 103.2 million, with INVO valued at USD 12.4 million and NAYA at USD 90.8 million. Shareholders of NAYA will receive ~7.33 shares of INVO for each share of NAYA.</p></li>
  <li><p>The merged company will be named "NAYA Biosciences" and will require shareholder approval and other closing conditions. The merger aims to strengthen INVO's fertility operations and expand its clinics across the US.</p></li>
  <li><p>INVO Bioscience, based in Florida, offers affordable fertility solutions. Its main product is INVOcell, a reproductive technology patented and FDA-cleared in 2016.</p></li>
 </ul>
</div>

INVO Bioscience enters merger agreement with NAYA Biosciences

REPROCELL, a biotech company based in Japan, has granted Gameto, a reproductive health company in the US, the right to use its StemRNA Clinical Seed-induced Pluripotent Stem Cells (iPSCs). Gameto will use these iPSCs in the development and commercialization of its IVF and egg-freezing process called Fertilo. Fertilo aims to mature oocytes outside of the body, reducing the hormonal burden on patients. The use of these iPSCs is expected to make IVF and egg freezing safer and more accessible, providing improved fertility care for women. REPROCELL focuses on stem-cell research and 3D bioengineered tissues, while Gameto specializes in treating women's reproductive health issues.

REPROCELL grants Gameto non-exclusive rights to use StemRNA Clinical Seed iPSCs

Oura, a company that develops wearable health-tracking devices, has introduced Cycle Insights, a new feature for its Oura Ring wearable. This feature provides menstrual cycle tracking and advanced insights by monitoring bodily functions and biomarkers such as temperature, heart rate, and heart rate variability. It combines this data with general health information to offer insights into how the body is affected by the menstrual cycle. Oura, founded in 2013, creates wearables that track activities and functions like sleep, fitness, wellness, heart rate, and menstrual cycles. The Oura Ring is paired with a companion app that provides insights, suggestions, and community features.

Oura Ring launches menstrual health features

Canadian fertility clinic Pollin Fertility has raised $20 million in a Series A funding round led by Osmington. The clinic, set to open in Toronto on October 16, aims to improve fertility treatment success rates with its state-of-the-art lab. Pollin Fertility, established in 2022, utilizes engineering, AI, and ML technologies to empower patients and provide advanced fertility treatments. Patients have full control over their fertility journey, interacting with their care navigator, accessing results instantly, and receiving necessary information. Other investors in the funding round include Melody Adhami, Sep Seyedi, David Diamond, and Michael Kimel.

Pollin Fertility raises USD 20 million in Series A funding

Home fertility solutions startup, Mosie Baby, has secured more than $1 million in a bridge round, surpassing its target and bringing its total funding to $1.2 million. Investors in the round include Magic Fund, The Fund Everywhere, The Council, and 37 Angels. The funds will be used to expand the company's retail partnerships and launch its kits with CVS and other mass retailers. Additionally, Mosie Baby has unveiled an updated home insemination kit that features patented Mosie Syringes and collection cups for semen collection and transfer.

All Updates